Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury.
Judith SommerChristoph DornErwin GäbeleFrauke BatailleKim FreeseTatjana SeitzWolfgang E ThaslerReinhard BüttnerRalf WeiskirchenAnja Katrin BosserhoffClaus HellerbrandPublished in: Cells (2020)
Cholestasis occurs in different clinical circumstances and leads to severe hepatic disorders. The four-and-a-half LIM-domain protein 2 (FHL2) is a scaffolding protein that modulates multiple signal transduction pathways in a tissue- and cell context-specific manner. In this study, we aimed to gain insight into the function of FHL2 in cholestatic liver injury. FHL2 expression was significantly increased in the bile duct ligation (BDL) model in mice. In Fhl2-deficient (Fhl2-ko) mice, BDL caused a more severe portal and parenchymal inflammation, extended portal fibrosis, higher serum transaminase levels, and higher pro-inflammatory and pro-fibrogenic gene expression compared to wild type (wt) mice. FHL2 depletion in HepG2 cells with siRNA resulted in a higher expression of the bile acid transporter Na+-taurocholate cotransporting polypeptide (NTCP) gene. Furthermore, FHL2-depleted HepG2 cells showed higher expression of markers for oxidative stress, lower B-cell lymphoma 2 (Bcl2) expression, and higher Bcl2-associated X protein (BAX) expression after stimulation with deoxycholic acid (DCA). In hepatic stellate cells (HSCs), FHL2 depletion caused an increased expression of TGF-β and several pro-fibrogenic matrix metalloproteinases. In summary, our study shows that deficiency in FHL2 aggravates cholestatic liver injury and suggests FHL2-mediated effects on bile acid metabolisms and HSCs as potential mechanisms for pronounced hepatocellular injury and fibrosis.
Keyphrases
- liver injury
- drug induced
- poor prognosis
- binding protein
- oxidative stress
- gene expression
- wild type
- type diabetes
- long non coding rna
- dna damage
- drug delivery
- protein protein
- risk assessment
- high fat diet induced
- cell death
- single cell
- metabolic syndrome
- signaling pathway
- liver fibrosis
- transforming growth factor
- skeletal muscle
- stem cells
- insulin resistance
- replacement therapy
- climate change
- human health